OLINGUITO: Filgotinib Meets Phase 3 Primary Endpoint in r/nr-axSpA, With Xenofon Baraliakos, MD, PhD
The first phase 3 data for filgotinib in axial spondyloarthritis show early, significant, and durable ASAS40 responses with no new safety signals through 52 weeks.
